

Pei Yang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7229994/pei-yang-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,006
citations

17
h-index

31
g-index

33
ext. papers

1,325
ext. citations

3.9
avg, IF

3.37
L-index

#	Paper	IF	Citations
30	Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma.. <i>Chinese Neurosurgical Journal</i> , 2022 , 8, 6	1.6	
29	A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma.. <i>BioMed Research International</i> , 2022 , 2022, 3194996	3	0
28	Integrated analysis of the genomic and transcriptional profile of high-grade gliomas in different age groups. <i>Clinical Immunology</i> , 2021 , 226, 108719	9	
27	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021 , 499, 60-72	9.9	61
26	Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2589-2600	7.4	1
25	A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 579-591	4.9	1
24	Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling. <i>Clinical Immunology</i> , 2020 , 216, 108430	9	7
23	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa098	0.9	0
22	High expression of VAT1 is a prognostic biomarker and predicts malignancy in glioblastoma. <i>Oncology Reports</i> , 2019 , 42, 1422-1430	3.5	2
21	Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. <i>Future Oncology</i> , 2018 , 14, 545-552	3.6	0
20	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. <i>Journal of Neurosurgery</i> , 2017 , 126, 249-259	3.2	15
19	Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. <i>Oncotarget</i> , 2017 , 8, 42974-42982	3.3	7
18	Clinicopathological factors predictive of postoperative seizures in patients with gliomas. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016 , 35, 93-9	3.2	24
17	Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1099-108	1	71
16	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. <i>Oncotarget</i> , 2016 , 7, 80091-80100	3.3	2
15	Classifying lower grade glioma cases according to whole genome gene expression. <i>Oncotarget</i> , 2016 , 7, 74031-74042	3.3	23
14	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , 2016 , 7, 16384-95	3.3	40

13	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016 , 7, 45005-45014	3.3	6
12	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016 , 375, 263-273	9.9	253
11	Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. <i>PLoS ONE</i> , 2015 , 10, e0126022	3.7	52
10	ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. <i>PLoS ONE</i> , 2015 , 10, e0142856	3.7	22
9	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. <i>Oncotarget</i> , 2015 , 6, 11676-82	3.3	18
8	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015 , 6, 7318-24	3.3	33
7	Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. <i>Oncotarget</i> , 2015 , 6, 18105-15	3.3	41
6	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015 , 6, 36643-51	3.3	32
5	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. <i>Oncotarget</i> , 2015 , 6, 40896-906	3.3	91
4	Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: a report of 198 patients from China. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014 , 23, 844-51	3.2	29
3	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. <i>Oncotarget</i> , 2014 , 5, 12908-15	3.3	48
2	Multidimensional analysis of gene expression reveals TGFBI1-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014 , 5, 12593-606	3.3	31
1	Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 259-66	4.8	92